查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612596

比伐盧定市場：按劑型、應用和最終用途 - 2025-2030 年全球預測

Bivalirudin Market by Dosage Form (Injection, Powder), Application (Angioplasty, Heparin-induced Thrombocytopenia, Percutaneous Coronary Intervention), End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年比伐盧定市場估值為12.3億美元，預計2024年將達到13.1億美元，預計複合年成長率為6.13%，到2030年將達到18.7億美元。

比伐盧定是一種直接凝血酶抑制劑，對於血栓性疾病的治療和管理至關重要，特別是對於接受經皮冠狀動脈介入治療 (PCI) 的患者。它對於血栓性疾病的治療和管理至關重要，特別是對於接受經皮冠狀動脈介入治療（PCI）的患者。它可以作為肝素的替代品，並具有可預測的藥物動力學和降低出血風險等優點。心血管疾病的日益普及和世界人口的老化推動了需求。影響比伐盧定市場的關鍵成長要素包括藥物輸送系統的進步、對更安全的抗凝血劑選擇的認知的提高以及血栓治療研究的進展。機會包括擴大核准和增加對廣泛治療適應症的使用，特別是在 PCI 治療呈上升趨勢的地區。此外，新興市場健康意識和醫療保健普及率的持續提高提供了進一步的市場潛力。然而，由於治療成本上升以及生物相似藥和非專利等替代抗凝血劑的競爭，該藥物仍存在一些限制。不斷變化的監管環境也增加了複雜性，並對市場擴張提出了挑戰。研究和創新應著重於改進配方，例如延長保存期限和改進遞送機制，這可以為門診和居家醫療鋪平道路。此外，進一步探索聯合治療可以增強其臨床效用，為個人化醫療鋪路。最佳化供應鏈策略可以提高成本效率和可近性，尤其是在低收入市場。公司必須緊跟監管變化，並對研發進行策略性投資，以利用未滿足的臨床需求。製藥公司、研究機構和醫療保健提供者之間的持續合作將有助於發揮成長潛力，克服現有的市場障礙，並將比伐盧定有效地整合到更廣泛的治療範式中。

主要市場統計
基準年[2023] 12.3億美元
預計年份 [2024] 13.1億美元
預測年份 [2030] 18.7億美元
複合年成長率（%） 6.13%

市場動態：揭示快速發展的比伐盧定市場的關鍵市場洞察

供需的動態交互作用正在改變比伐盧定市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 對有效治療心血管疾病的抗凝血劑的需求增加
    • 消費者在改良藥品和藥品上的支出增加
  • 市場限制因素
    • 與替代品相比，比伐盧定的特性昂貴
  • 市場機會
    • 即用型比伐盧定製劑的開發進展
    • 政府繼續核准新產品
  • 市場問題
    • 與使用比伐盧定相關的風險和併發症

波特的五力：駕馭比伐盧定市場的策略工具

波特的五力架構是了解比伐盧定市場競爭格局的關鍵工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解比伐盧定市場的外部影響

外部宏觀環境因素在塑造比伐盧定市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解比伐盧定市場的競爭格局

比伐盧定市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV 定位矩陣：比伐盧定市場供應商績效評估

FPNV定位矩陣是評估比伐盧定市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製比伐盧定市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，比伐盧定市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 對治療心血管疾病的有效抗凝血劑的需求日益成長。
      • 增加消費者在藥品和藥品改善的支出
    • 抑制因素
      • 與其他選擇相比，比伐盧定價格昂貴
    • 機會
      • 即用組合藥物的開發
      • 政府正在核准新產品
    • 任務
      • 與使用比伐盧定相關的風險和併發症
  • 市場區隔分析
    • 劑型：比伐盧定在外科手術中常以注射劑的形式使用。
    • 最終用途：比伐盧定在門診手術中心的新用途
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章比伐盧定市場：按劑型

  • 介紹
  • 注射
  • 粉末

第7章 比伐盧定市場：依應用分類

  • 介紹
  • 血管成形術
  • 肝素誘發的血小板減少性疾病
  • 經皮冠狀動脈介入治療

第 8 章 比伐盧定市場：依最終用途分類

  • 介紹
  • 門診手術中心
  • 醫院/診所
  • 專科診所

第9章 北美、南美洲比伐盧定市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太比伐盧定市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲比伐盧定市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Avenacy 推出非專利琴酒注射液，擴大了美國抗凝血藥物的選擇
    • 遠藤國際推出即用型比伐盧定注射液以提高臨床效率
    • 遠藤國際宣佈建立戰略合作關係，並分銷美國即用型比伐盧定注射液
  • 戰略分析和建議

公司名單

  • Apotex Inc.
  • Aurobindo Pharma
  • Avenacy, Inc.
  • Baxter International
  • Cayman Chemical
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Endo International plc
  • Eugia US LLC
  • Fresenius Kabi
  • Meitheal Pharmaceuticals, Inc.
  • Merck KGaA
  • Midas Pharma GmbH
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-7A22CB0E5BB3

The Bivalirudin Market was valued at USD 1.23 billion in 2023, expected to reach USD 1.31 billion in 2024, and is projected to grow at a CAGR of 6.13%, to USD 1.87 billion by 2030.

Bivalirudin, a direct thrombin inhibitor, is critical in the treatment and management of thrombotic conditions, particularly for patients undergoing percutaneous coronary interventions (PCI). Its application serves as an alternative to heparin, showcasing benefits such as predictable pharmacokinetics and reduced bleeding risk. The demand is driven by the growing prevalence of cardiovascular diseases and an aging global population. Key growth factors influencing the bivalirudin market include advancements in drug delivery systems, increasing awareness about safer anticoagulant options, and ongoing research in thrombotic therapies. Opportunities lie in expanding approvals and increasing usage in broader therapeutic indications, particularly in regions with rising PCI procedures. Moreover, the continuous rise in health awareness and access to healthcare in emerging markets provides additional market potential. However, limitations exist due to the high costs of therapy and competitive pressure from alternative anticoagulants, including biosimilars and generics. The evolving regulatory landscape adds another layer of complexity, challenging market expansion. Research and innovation should focus on enhancing bivalirudin formulations for extended shelf life and improved delivery mechanisms, potentially opening more avenues for outpatient and home-based care settings. Further exploration in combination therapies could also augment its clinical utility - paving the way for personalized medicine approaches. Optimizing supply chain strategies can improve cost efficiency and accessibility, particularly in low-income markets, which will be a critical determinant of future market growth. Businesses must stay abreast of regulatory shifts and invest strategically in R&D to leverage unmet clinical needs. Continued collaboration between pharmaceutical companies, research institutions, and healthcare providers will be vital for harnessing potential growth and overcoming existing market barriers, ensuring the effective integration of bivalirudin into more extensive therapeutic paradigms.

KEY MARKET STATISTICS
Base Year [2023] USD 1.23 billion
Estimated Year [2024] USD 1.31 billion
Forecast Year [2030] USD 1.87 billion
CAGR (%) 6.13%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bivalirudin Market

The Bivalirudin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing need for effective anticoagulants to treat cardiovascular disorders
    • Growing consumer expenditure for improved drug and medications
  • Market Restraints
    • Expensive nature of bivalirudin compared to the alternatives
  • Market Opportunities
    • Emerging development of ready-to-use bivalirudin formulations
    • Ongoing government approvals for new products
  • Market Challenges
    • Risks and complexities associated with use of bivalirudin

Porter's Five Forces: A Strategic Tool for Navigating the Bivalirudin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bivalirudin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bivalirudin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bivalirudin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bivalirudin Market

A detailed market share analysis in the Bivalirudin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bivalirudin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bivalirudin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bivalirudin Market

A strategic analysis of the Bivalirudin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bivalirudin Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Aurobindo Pharma, Avenacy, Inc., Baxter International, Cayman Chemical, Cipla Limited, Dr. Reddy's Laboratories, Endo International plc, Eugia US LLC, Fresenius Kabi, Meitheal Pharmaceuticals, Inc., Merck KGaA, Midas Pharma GmbH, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Bivalirudin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Dosage Form, market is studied across Injection and Powder.
  • Based on Application, market is studied across Angioplasty, Heparin-induced Thrombocytopenia, and Percutaneous Coronary Intervention.
  • Based on End-Use, market is studied across Ambulatory Surgical Centers, Hospitals & Clinics, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing need for effective anticoagulants to treat cardiovascular disorders
      • 5.1.1.2. Growing consumer expenditure for improved drug and medications
    • 5.1.2. Restraints
      • 5.1.2.1. Expensive nature of bivalirudin compared to the alternatives
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging development of ready-to-use bivalirudin formulations
      • 5.1.3.2. Ongoing government approvals for new products
    • 5.1.4. Challenges
      • 5.1.4.1. Risks and complexities associated with use of bivalirudin
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Dosage Form: Significant usage of bivalirudin in injectable form during surgical procedures
    • 5.2.2. End-Use: Emerging usage of bivalirudin in ambulatory surgical centers
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bivalirudin Market, by Dosage Form

  • 6.1. Introduction
  • 6.2. Injection
  • 6.3. Powder

7. Bivalirudin Market, by Application

  • 7.1. Introduction
  • 7.2. Angioplasty
  • 7.3. Heparin-induced Thrombocytopenia
  • 7.4. Percutaneous Coronary Intervention

8. Bivalirudin Market, by End-Use

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals & Clinics
  • 8.4. Specialty Clinics

9. Americas Bivalirudin Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bivalirudin Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bivalirudin Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Avenacy Introduces Generic Bivalirudin Injection, Expanding Anticoagulant Options in the U.S.
    • 12.3.2. Endo International Launches Ready-to-Use Bivalirudin Injection Enhancing Clinical Efficiency
    • 12.3.3. Endo International Announces Strategic Partnership for U.S. Distribution of Ready-to-Use Bivalirudin Injection
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Apotex Inc.
  • 2. Aurobindo Pharma
  • 3. Avenacy, Inc.
  • 4. Baxter International
  • 5. Cayman Chemical
  • 6. Cipla Limited
  • 7. Dr. Reddy's Laboratories
  • 8. Endo International plc
  • 9. Eugia US LLC
  • 10. Fresenius Kabi
  • 11. Meitheal Pharmaceuticals, Inc.
  • 12. Merck KGaA
  • 13. Midas Pharma GmbH
  • 14. Pfizer Inc.
  • 15. Teva Pharmaceutical Industries Ltd.
  • 16. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. BIVALIRUDIN MARKET RESEARCH PROCESS
  • FIGURE 2. BIVALIRUDIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIVALIRUDIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BIVALIRUDIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BIVALIRUDIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIVALIRUDIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIVALIRUDIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIVALIRUDIN MARKET DYNAMICS
  • TABLE 7. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIVALIRUDIN MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIVALIRUDIN MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIVALIRUDIN MARKET SIZE, BY ANGIOPLASTY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIVALIRUDIN MARKET SIZE, BY HEPARIN-INDUCED THROMBOCYTOPENIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIVALIRUDIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. BIVALIRUDIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. BIVALIRUDIN MARKET, FPNV POSITIONING MATRIX, 2023